<DOC>
	<DOC>NCT01458574</DOC>
	<brief_summary>The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.</brief_summary>
	<brief_title>A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects who met study entry criteria and completed 8week induction treatment from Study A3921094 or A3921095 Subjects who achieved clinical response in Study A3921094 or A3921095 Women of childbearing potential must test negative for pregnancy prior to study enrollment Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Evidence of a personally signed and dated informed consent document(s) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Subjects who had major protocol violation (as determined by the Sponsor) in Study A3921094 or A3921095 Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease Subjects who have had surgery for UC or in the opinion of the investigator, are likely to require surgery for UC during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Janus kinase inhibitor</keyword>
	<keyword>JAK 3 inhibitor</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>ulcerative colitis</keyword>
	<keyword>OCTAVE</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
</DOC>